US Tariffs on Generic Drugs: A Looming Challenge for India's Pharma Sector

US President Donald Trump has declared plans to impose a substantial 100 per cent tariff on imported generic pharmaceuticals, effective August 2028. The move, announced on Tuesday, is reportedly aimed at incentivising the return of drug manufacturing to American soil and bolstering the nation's domestic production capabilities.

This policy initiative underscores a broader strategy to decrease the United States' reliance on foreign drug manufacturers and enhance the resilience of its pharmaceutical supply chain. By levying such high duties, the former President intends to make imported generic drugs significantly more expensive, thereby making domestic production more competitive and attractive for pharmaceutical companies.

For India, a global hub for generic drug production and a major exporter to the US market, this announcement carries considerable weight. Indian pharmaceutical firms supply a significant portion of generic medications consumed in the United States. Should these tariffs come into effect, they could pose a substantial challenge to India's pharmaceutical exports, potentially impacting revenues and market share for leading Indian drug manufacturers.

The long lead time until August 2028 provides a window for Indian companies and the Indian government to assess the potential ramifications and strategise responses. However, the proposed tariffs signal a significant shift in US trade policy concerning essential medicines, necessitating careful consideration of its long-term implications for global pharmaceutical trade and supply chain dynamics.